Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume 19, Issue 11, Pages 1061-1074
Publisher
Informa UK Limited
Online
2016-05-26
DOI
10.1080/13696998.2016.1194278
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
- (2015) M. A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States
- (2015) Xue Song et al. CURRENT MEDICAL RESEARCH AND OPINION
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Sequencing Patterns And Costs of Care in Patients with Relapsed/Refractory Multiple Myeloma
- (2015) R Potluri et al. VALUE IN HEALTH
- Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
- (2015) S. Z. Usmani et al. JOURNAL OF MEDICAL ECONOMICS
- Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma
- (2014) Irina Proskorovsky et al. Health and Quality of Life Outcomes
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent improvement in survival of patients with multiple myeloma: variation by ethnicity
- (2013) Dianne Pulte et al. LEUKEMIA & LYMPHOMA
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data
- (2013) Nicholas R. Latimer MEDICAL DECISION MAKING
- Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study
- (2013) Karin Jordan et al. SUPPORTIVE CARE IN CANCER
- Total cost comparison in relapsed/refractory multiple myeloma
- (2013) Brian Durie et al. JOURNAL OF MEDICAL ECONOMICS
- Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry
- (2012) Floortje Mols et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
- (2012) Peter A. Ubel et al. HEALTH AFFAIRS
- Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2012) Laurent Garderet et al. JOURNAL OF CLINICAL ONCOLOGY
- cells making IL-17
- (2011) B. Silva-Santos BLOOD
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study
- (2010) Kathleen M Beusterien et al. Health and Quality of Life Outcomes
- Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study
- (2010) X. Armoiry et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
- (2009) Bruce E. Hillner et al. JOURNAL OF CLINICAL ONCOLOGY
- What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?
- (2009) R Scott Braithwaite et al. MEDICAL CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started